Avacta Share Discussion Threads

[money multipier] 07/11/2019 16:44

Whilst it's nice to have a good day, lets not get to carried away here. The only ones to be in profit here are those who have bought in the last 3 weeks, and not likely any long term holders or anyone who has averaged down. Avacta has had to raise money at a very low price with a big dilution to existing holders, presumably because they couldn't sell the story at a higher price. If there are mega deals around the corner, why didn't they do these first and raise money at a higher price? I've thrown too much in here already to risk anymore.
I just hope they have enough cash to get through a successful trial and can move to a price many multiples of today's price, because that's the only way I'm going to get in profit. They clearly weren't able to raise enough to progress both AVA6000 and AVA004, with the latter being paused.
Obviously I'm pleased with the rise today, but they certainly haven't shown themselves to be a fast moving deal making company, and the £1.25 will not be current based on the latest dilution and pausing AVA6000.

[nordic1958] 07/11/2019 16:03

WellI think we now have a very different Avacta and fast moving deal making company as well.Very confident of an interesting Q4

[patio58] 07/11/2019 15:55

If I recall, finnCapp had a £1.25 target price on this, still think that's current so plenty of uplift hopefully.

[nordic1958] 07/11/2019 15:39

I would as well.The whole Oncology area is the hottest place to be in bio tech.Suspect we will see more deals to be announced.

[patio58] 07/11/2019 15:31

Hi Nordic, I am a holder, just a bit despondent with the fall this year, after being well up on my holdings, I'm now a bit down, might top up if this price holds.

[nordic1958] 07/11/2019 15:23

Well, the company have complete the equity placing, with a high profile small cap fund management group popping up with a + 5% share holding, Have entered into a R&D pact with ADC Therapeutics ( backed by Astra Zeneca ) and I would not be surprised if AZN adds Avacta to their pre Clinical Assets partners.Suspect an interesting Q4 coming up with further announcements as a result of additional new commercial deals fully funded by the various new partners, as mentioned in the company presentations.Would buy more here

[patio58] 07/11/2019 14:52

Mmm.... something brewing here, perhaps an announcement is due??!

[nordic1958] 07/11/2019 11:26

Miton Group now holds + 5% post equity raise.Top quality and high profile share holder.Excellent news and strong validation of the company

[nordic1958] 07/11/2019 10:43

I would expect Q4 to have further news on new license deals etcThis company could be a fantastic performer with such a pipe line. Read their investor presentation

[patio58] 07/11/2019 10:39

Unfortunately we have new investors who have bought in at 15p and will probably sell into any rise, as there is low trading volumes here it might take ages to clear the overhang. Hope I'm wrong.

[bumpa33] 07/11/2019 09:49

Told by an mm that 1.7m was a seller cleared, took 100k this morning. Not exactly chuffed with the share price performance, heard a rumor or two re the fund raise a number of weeks back and registered interest but got nothing back. Nice to see Mitón now involved. Time for this bloody company to start delivering.

First time in an age the stock has been bid though.

[escapetohome] 07/11/2019 09:24

Up ! ye Gods!

[mikro1] 07/11/2019 09:21

I agree, now that the fundraising is done and the company wont need more money for at least 12 months - and hopefully never if the trial goes well - this should rise from here, and rocket on good news. I've bought some more this morning.

[nordic1958] 06/11/2019 14:22

IndeedThis equity raise gives the company working room and time for further expansion.More collaborations to be announced I am sure of

[losses] 06/11/2019 11:13

I thought this would higher once the placing was successful?

[money multipier] 31/10/2019 23:37

Update from Edison:

[nordic1958] 31/10/2019 12:39

Interesting article of update from AVacta's partner in Korea and their expansion plans.

[sunningdale1] 25/10/2019 16:12

Keep holding guys this is one for the long-term. Significant upside will be achieved here over the next 3 years.

For those interested in other Pharma stocks (if you're not, no problem - this is a shameless plug) Open Orphan AIM:ORPH is one I’d recommend keeping an eye on - Share price has performed well over the last 6 months and it's no surprise - CEO Cathal Friel predicts 40% growth a year on podcast below with 2 million of his own money invested. hxxps://audioboom.com/posts/7361662-open-orphan-orph-ceo-cathal-friel-tells-alan-green-why-he-expects-40-percent-growth-year-on-year

Their health databank a standout for me and is progressing well. ORPH recently signed an agreement with Empiric Logic, a leading managed software service company. The Collaboration is the final stage in the completion of Open Orphan’s Genomic Health Data platform and will speed up its launch. The companies CCO Maurice Treacy is holding a live webinar on Wednesday 30th October 2019 at 19:00 (UK time) for those interested: hxxps://vtm.clickmeeting.com/orph

[cheshire pete] 25/10/2019 11:38

nordic1958: "Astra Zeneca approved this ADC deal"

Encouraging if AZN also think it may have potential.

[nordic1958] 23/10/2019 11:26

However...We now have clinical human trials ahead of scheduleContinued acceleration in Collaborations I think you will find earnings revision upwards for next year and onwards.Interesting couple of quarters going forward

[poacher45] 23/10/2019 11:16

Alastair promised nine years ago that they would be making a profit in two years.
Every two years he has a rights issue and big promises are made and nothing happens. The only thing that goes up is expenses and salaries. It will soon be time for another consolidation probably 10 shares for one new one.

[nordic1958] 23/10/2019 10:51

It is the hottest area in the health care sector and there is continued JV's and majors injecting cash into the sector.Watch out for Eli Lilly results today, more on the sector

[money multipier] 23/10/2019 10:28

Also note from the funding RNS that for AVA004, first-time-in-human trials of the Affimer(R) platform the costs of manufacturing would be £5M so this will go on hold when they get to this stage. A subtly introduced delay!
On the plus side the price has hit the placing price and looks to have bounced up.

[money multipier] 23/10/2019 08:33

.....Alastair suggests in both the results and his interview that a successful trial will lead to large licencing deals with up-fronts that will be able to provide all future funding.